Zheng Lingzi, Hu Ling, Badehnoosh Bita
First Clinical Institute, Faculty of Medicine, Wuhan University of Science and Technology, Wuhan, 430064, Hubei, China.
Tianyou Hospital, Affiliated to Wuhan University of Science and Technology, Wuhan, 430064, Hubei, China.
Cancer Cell Int. 2025 Jul 11;25(1):256. doi: 10.1186/s12935-025-03895-8.
Cancer remains one of the most formidable global health challenges due to its complex pathogenesis, late-stage diagnosis, and limited therapeutic options for many subtypes. Despite advancements in reducing cancer-related mortality through lifestyle modifications and early interventions, it continues to rank among the top ten causes of death worldwide. A growing body of evidence highlights the critical role of non-coding RNAs, particularly microRNAs (miRNAs), in cancer biology. MiRNAs are short, non-coding RNA molecules approximately 19-25 nucleotides in length that regulate gene expression at the post-transcriptional level. Among these, miRNA-1303 has garnered increasing attention due to its aberrant expression across a variety of malignancies and its involvement in diverse cellular processes, including cell proliferation, apoptosis, migration, invasion, and chemoresistance. In this review, we provide a comprehensive overview of miRNA-1303, emphasizing its dysregulation in different cancer types such as colorectal, breast, prostate, and lung cancers. We explore the molecular mechanisms and signaling pathways modulated by miRNA-1303, including its interaction with oncogenes, tumor suppressors, and key cellular networks like PI3K/AKT, Wnt/β-catenin, and MAPK pathways. We also discuss its functional role in tumor development and progression, supported by both in vitro and in vivo studies. Furthermore, we evaluate the potential of miRNA-1303 as a clinically relevant biomarker for early cancer detection, prognosis prediction, and treatment monitoring. Its expression patterns have been correlated with tumor stage, metastasis, and patient survival, suggesting promising utility in clinical decision-making. In addition, we explore the emerging therapeutic strategies targeting miRNA-1303, including miRNA mimics, inhibitors, and delivery systems designed to modulate its expression in cancer cells. By synthesizing current findings, this review underscores the clinical significance of miRNA-1303 in oncology and proposes future directions for its application in personalized medicine.
由于癌症发病机制复杂、诊断晚期以及许多亚型的治疗选择有限，它仍然是全球最严峻的健康挑战之一。尽管通过生活方式改变和早期干预在降低癌症相关死亡率方面取得了进展，但它仍是全球十大死因之一。越来越多的证据凸显了非编码RNA，尤其是微小RNA（miRNA）在癌症生物学中的关键作用。miRNA是长度约为19 - 25个核苷酸的短链非编码RNA分子，在转录后水平调节基因表达。其中，miRNA - 1303因其在多种恶性肿瘤中的异常表达及其参与包括细胞增殖、凋亡、迁移、侵袭和化疗耐药等多种细胞过程而受到越来越多的关注。在本综述中，我们全面概述了miRNA - 1303，强调其在不同癌症类型如结直肠癌、乳腺癌、前列腺癌和肺癌中的失调。我们探讨了由miRNA - 1303调节的分子机制和信号通路，包括其与癌基因、肿瘤抑制因子以及PI3K/AKT、Wnt/β - 连环蛋白和MAPK等关键细胞网络的相互作用。我们还讨论了其在肿瘤发生和发展中的功能作用，这得到了体外和体内研究的支持。此外，我们评估了miRNA - 1303作为早期癌症检测、预后预测和治疗监测的临床相关生物标志物的潜力。其表达模式已与肿瘤分期、转移和患者生存率相关，表明在临床决策中具有广阔的应用前景。此外，我们探讨了针对miRNA - 1303的新兴治疗策略，包括旨在调节其在癌细胞中表达的miRNA模拟物、抑制剂和递送系统。通过综合当前的研究结果，本综述强调了miRNA - 1303在肿瘤学中的临床意义，并提出了其在个性化医学中应用的未来方向。
